Novel Discoveries in Immune Dysregulation in Inborn Errors of Immunity.
Détails
Télécharger: 34512655_BIB_5ABC78DF7B11.pdf (466.80 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_5ABC78DF7B11
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Novel Discoveries in Immune Dysregulation in Inborn Errors of Immunity.
Périodique
Frontiers in immunology
ISSN
1664-3224 (Electronic)
ISSN-L
1664-3224
Statut éditorial
Publié
Date de publication
2021
Peer-reviewed
Oui
Volume
12
Pages
725587
Langue
anglais
Notes
Publication types: Journal Article ; Review ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Publication Status: epublish
Résumé
With the expansion of our knowledge on inborn errors of immunity (IEI), it gradually becomes clear that immune dysregulation plays an important part. In some cases, autoimmunity, hyperinflammation and lymphoproliferation are far more serious than infections. Thus, immune dysregulation has become significant in disease monitoring and treatment. In recent years, the wide application of whole-exome sequencing/whole-genome sequencing has tremendously promoted the discovery and further studies of new IEI. The number of discovered IEI is growing rapidly, followed by numerous studies of their pathogenesis and therapy. In this review, we focus on novel discovered primary immune dysregulation diseases, including deficiency of SLC7A7, CD122, DEF6, FERMT1, TGFB1, RIPK1, CD137, TET2 and SOCS1. We discuss their genetic mutation, symptoms and current therapeutic methods, and point out the gaps in this field.
Mots-clé
autoimmunity, hyperinflammation, immune dysregulation, inborn errors of immunity, lymphoproliferation, primary immune dysregulation disease
Pubmed
Web of science
Open Access
Oui
Création de la notice
21/09/2021 10:48
Dernière modification de la notice
12/01/2022 7:10